MedTrace Logo

Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders

NCT02567175 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-08-01

No results posted yet for this study

Summary

FDA currently allows patients 12 years of age and older with various gastrointestinal (GI) conditions to be treated with Domperidone through the Expanded Access to Investigational Drugs program. These conditions include gastroesophageal reflux disease with upper GI symptoms, gastroparesis, and chronic constipation. Patients must have failed standard therapies to be eligible to receive Domperidone. This program facilitates availability of investigational drugs, (such as Domperidone) to patients with serious diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease or condition.

Conditions

  • Gastroesophageal Reflux
  • Gastroparesis
  • Chronic Constipation With Overflow
  • Pseudo Obstruction

Interventions

DRUG

Domperidone

Sponsors & Collaborators

  • Prasanna K Kapavarapu

    lead OTHER

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02567175 on ClinicalTrials.gov